Hostname: page-component-7479d7b7d-m9pkr Total loading time: 0 Render date: 2024-07-11T01:52:58.589Z Has data issue: false hasContentIssue false

The cannabis profile: A high-risk subtype

Published online by Cambridge University Press:  23 March 2020

R. Landera Rodríguez
Affiliation:
Hospital Universitario Marqués de Valdecilla, psychiatry, Santander, Spain
M. Gómez Revuelta
Affiliation:
Hospital Universitario de Álava-Sede Santiago, psychiatry, Vitoria-Gastéiz, Spain
J.L. García Egea
Affiliation:
Hospital Universitario Virgen del Rocío, psychiatry, Sevilla, Spain
O. Porta Olivares
Affiliation:
Hospital Universitario Marqués de Valdecilla, psychiatry, Santander, Spain
M. Juncal Ruíz
Affiliation:
Hospital Universitario Marqués de Valdecilla, psychiatry, Santander, Spain
M. Pérez Herrera
Affiliation:
Hospital Universitario Marqués de Valdecilla, psychiatry, Santander, Spain
L. Sánchez Blanco
Affiliation:
Hospital Universitario Marqués de Valdecilla, psychiatry, Santander, Spain
D. Abejas Díez
Affiliation:
Hospital Universitario Marqués de Valdecilla, psychiatry, Santander, Spain
G. Pardo de Santayana Jenaro
Affiliation:
Hospital Universitario Marqués de Valdecilla, psychiatry, Santander, Spain
M. Fernández Rodríguez
Affiliation:
Hospital Universitario Marqués de Valdecilla, general medicine, Santander, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The first phase following the diagnosis of a first psychotic episode (FEP), is crucial to determine clinical and functional long-term outcome. Cannabis exerts a mediating action on the debut of the disease and determines a poor prognosis.

Objectives

The description of a specific population profile of increased vulnerability to maintain cannabis use after a FEP could help to identify this high risk subtype of patients and speed up the implementation of specific interventions.

Materials and methods

One hundred and seventy-eight patients were recruited from PAFIP (early intervention program on FEP), obtaining detailed socio-demographic assessment. They were followed-up for a year during which cannabis consumption was assessed by Drake scale every three months. We divided the sample into two groups:

– those patients who neither smoked cannabis before the FEP nor during follow-up period (nn);

– consumers group: cannabis users before the FEP who kept on smoking during the follow-up period (ss) and those who smoked before the FEP and gave up consumption during follow-up (sn).

Results

Statistically significant differences between groups were observed. The consumers group (ss + sn) had an earlier age of onset, most were male, unemployed, single, prone to loneliness and they were concomitant users of alcohol and tobacco.

Conclusions

The use of cannabis has a detrimental effect on the outcome of schizophrenia. A specific and early intervention could contribute to prognostic improvements. Identifying cannabis consumption subtypes could be useful for this purpose.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Walk: Comorbidity/Dual pathologies and guidelines/Guidance - Part 2
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.